Ann: Appendix 4C - Quarter Ended 31 March 2016-IPD.AX, page-5

1) finding they are selling multiple machines (L-Dex) to each cancer centre..(surgery and outpatients)
2) there will be 17 tests per patient over 5 years of cancer survivorship
3) with 17 centres signed up all ready, confident they will beat their target of over 50 centres by end of year.
4) private pay reimbursement (needs medicare approval) is key success aim is for 2016/7 as this will drive additional uptake and revenue
5) 1100 person clinical trial will reach full enrolement by end of year.. with first release data release end of 2016 early 2017. This should build a strong clinical case for the adoption of their product in the field
6) NCCN (Cancer guidelines) guidelines..aiming for inclusion of bio spectroscopy as standard of care (currently centres are recommended to test Lymphodema but not specifically using bio spectroscopy)
7) capital raising of $70m has helped develop the next generation of device faster with more engineers working on development. Will include the ability for home testing which opens up further potential revenue..
8) Development of heart failure product is also accelerating with a market ready product scheduled for mid 2017.
9) key learnings from trial programme in 2015 has allowed sales team to focus on presenting to the clinical review groups for cancer centres as they are key decision makers.
10) current headcount: 55 employees